Enhanced Intervertebral Disc Repair via Genetically Engineered Mesenchymal Stem Cells with Tetracycline Regulatory...

Area of Science:

• Regenerative Medicine
• Stem Cell Biology
• Orthopedics

Background:

• Intervertebral disc (IVD) degeneration is a significant cause of back pain and disability.
• Mesenchymal stem cells (MSCs) offer therapeutic potential for IVD degeneration.
• Enhancing MSCs with specific cytokines can improve their efficacy.

Purpose of the Study:

• To investigate the therapeutic potential of engineered tonsil-derived MSCs (ToMSC-Tetoff-TGFβ1-IGF1-BMP7) for IVD degeneration.
• To assess the efficacy of genetically modified MSCs in a rat model of disc injury.
• To evaluate the impact of enhanced MSCs on nucleus pulposus regeneration and extracellular matrix restoration.

Main Methods:

• Isolation and genetic modification of tonsil-derived MSCs (ToMSCs) using CRISPR/Cas9.
• Confirmation of transgene expression and protein secretion (TGFβ1).
• Assessment of therapeutic effects in a rat IVD degeneration model.

Main Results:

• ToMSC-Tetoff-TGFβ1-IGF1-BMP7 demonstrated superior therapeutic effects compared to control groups.
• The treatment stimulated nucleus pulposus (NP) cell regeneration.
• Restoration of extracellular matrix (ECM) components (aggrecan, type II collagen), anti-inflammatory effects, and pain reduction were observed.

Conclusions:

• Engineered ToMSC-Tetoff-TGFβ1-IGF1-BMP7 holds significant promise for treating IVD degeneration.
• The therapy promotes NP cell regeneration, ECM repair, and exhibits anti-inflammatory and analgesic properties.
• Further research and clinical trials are necessary to validate its therapeutic potential.